

March 2, 2026

Mochida Pharmaceutical Co., Ltd.  
Meiji Seika Pharma Co., Ltd.

## **Announcement of the Launch of Epadel in Vietnam**

Mochida Pharmaceutical Co., Ltd. (Head office: Shinjuku-ku, Tokyo, President: Naoyuki Mochida, hereinafter, "Mochida") and Meiji Seika Pharma Co., Ltd. (Head office: Chuo-ku, Tokyo, President: Toshiaki Nagasato, hereinafter, "Meiji") announced that on February 23, 2026, Thien Thao Pharmaceutical Joint Stock Company (Head office: Hanoi, Vietnam, hereinafter, "Thien Thao"), a partner of Meiji, launched EPADEL S900 (product name in Japan: Epadel S900) in Vietnam. Epadel is a highly purified eicosapentaenoic acid (EPA) ethyl ester formulation sold by Mochida in Japan.

Mochida has granted Meiji exclusive rights to develop and market EPADEL S900 in Vietnam. Meiji supported Thien Thao's application for marketing authorization, and on June 16, 2025, Thien Thao obtained approval to import and market EPADEL S900.

Mochida will supply EPADEL S900 for the Vietnamese market, while Meiji will exclusively market the product through Thien Thao in Vietnam. Mochida will also provide support to Thien Thao through Meiji.

Mochida and Meiji have entered into an agreement covering the sale of Epadel in the ASEAN region, including Thailand, as well as in China and Taiwan. At present, Epadel is sold in Thailand, and has already been approved in China, where preparations for its launch are underway. Following this launch, Mochida and Meiji will contribute to improving patients' quality of life by providing EPADEL S900 as a new treatment option for hyperlipidemia in Vietnam.

### About Epadel

Epadel is a highly purified EPA ethyl ester formulation developed by Mochida as the world's first prescription EPA ethyl ester product. The active pharmaceutical ingredient is supplied by Nissui Corporation, which has advanced EPA purification technology and mass-production capacity. Since its launch in 1990, it has been taken by many patients, as the flagship drug of Mochida.

### About Thien Thao Pharmaceutical Joint Stock Company

Thien Thao was established in 1995 in Hanoi, Vietnam, and provides pharmaceutical and healthcare products. Meiji entered into a comprehensive partnership agreement with Thien Thao in 2012. Since then, Thien Thao has been engaged in sales of antibiotics and other products.

[References]

Summary of EPADEL S900

Product Name : EPADEL S900  
Generic Name : Ethyl Icosapentate  
Indications : Hyperlipidemia  
Dosage and Administration : The usual adult dosage for oral use is 1 sachet (900 mg as Ethyl Icosapentate) twice daily immediately after meals. However, in cases of elevated triglyceride levels, the dose may be increased to 1 sachet per dose, administered 3 times daily, depending on the severity of the abnormalities.  
Approval Date : June 16, 2025  
Launch Date : February 23, 2026

###

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.